BIOLASE, Inc. has received regulatory clearance for Laser Bacterial Reduction (LBR) therapy indication from the FDA.
BIOLASE, Inc. has received regulatory clearance for Laser Bacterial Reduction (LBR) therapy indication from the FDA, the company announced this week.
The LBR indication now allows for the early management of periodontal disease utilizing laser light energy to reduce bacteria, reportedly decreasing inflammation and enhancing periodontal health.
"We are extremely pleased that this new indication has been cleared by the FDA for the Epic Hygiene Laser," said BIOLASE CEO, Todd Norbe. "With this clearance, we can further expand the types of procedures hygienists can perform, directly aligning with our mission of advancing dentistry across all fields. We also believe this new indication will directly benet patients by providing a virtually-pain free and faster treatment option."
Released in December 2019, the Epic Hygiene Laser is specifically designed for dental hygienists and allows hygienists to perform gentler, highly effective treatments for bacterial reduction and managing periodontal disease.
The Epic Hygiene has also received clearance for the removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium.
For more information, visit go.biolase.com/epichygiene.